Biotech Values

[DewDiligence]

ABBV/Roche—Registrational phase-2 Venetoclax* trial succeeds in CLL:

http://finance.yahoo.com/news/phase-2-study-venetoclax-patients-123000896.html

AbbVie…today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

…Data from this study will be presented at an upcoming medical conference and will serve as the pivotal registration data for applications to the FDA, EMA and other health authorities. The safety profile was similar to previous studies and no unexpected safety signals were reported for venetoclax.

*f/k/a ABT-199.